blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1962835

EP1962835 - TREATMENT OF NONALCOHOLIC FATTY LIVER DISEASE USING CHOLESTEROL LOWERING AGENTS AND/OR H3 RECEPTOR ANTAGONIST/INVERSE AGONIST [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  25.02.2011
Database last updated on 31.08.2024
Most recent event   Tooltip25.02.2011Application deemed to be withdrawnpublished on 30.03.2011  [2011/13]
Applicant(s)For all designated states
Schering Corporation
2000 Galloping Hill Road
Kenilworth, NJ 07033-0530 / US
[2008/36]
Inventor(s)01 / HWA, Joyce, J.
909 Prospect Street
Westfield, NJ 07090 / US
02 / VAN HEEK, Margaret
1851 Raritan Road
Scotch Plains, NJ 07076 / US
03 / DAVIS, Harry, Jr.
64 River Bend Road
Berkeley Heights, NJ 07922 / US
 [2008/36]
Representative(s)Hoffmann Eitle
Patent- und Rechtsanwälte PartmbB
Arabellastrasse 30
81925 München / DE
[N/P]
Former [2008/36]HOFFMANN EITLE
Patent- und Rechtsanwälte Arabellastrasse 4
81925 München / DE
Application number, filing date06845826.419.12.2006
[2008/36]
WO2006US48455
Priority number, dateUS20050752710P21.12.2005         Original published format: US 752710 P
US20060787048P29.03.2006         Original published format: US 787048 P
US20060836642P09.08.2006         Original published format: US 836642 P
US20060855178P30.10.2006         Original published format: US 855178 P
[2008/36]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2007075702
Date:05.07.2007
Language:EN
[2007/27]
Type: A2 Application without search report 
No.:EP1962835
Date:03.09.2008
Language:EN
The application published by WIPO in one of the EPO official languages on 05.07.2007 takes the place of the publication of the European patent application.
[2008/36]
Search report(s)International search report - published on:EP16.08.2007
ClassificationIPC:A61K31/397, A61K31/445, A61P3/06, A61P3/10
[2008/36]
CPC:
A61K31/397 (EP,US); A61K31/445 (EP,US); A61K31/7052 (EP,US);
A61K45/06 (EP,US); A61P1/16 (EP); A61P3/04 (EP);
A61P3/06 (EP); A61P3/10 (EP); A61P43/00 (EP) (-)
C-Set:
A61K31/397, A61K2300/00 (EP,US);
A61K31/445, A61K2300/00 (US,EP);
A61K31/7052, A61K2300/00 (US,EP)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2008/36]
Extension statesAL28.03.2008
BA28.03.2008
HR28.03.2008
MK28.03.2008
RS28.03.2008
TitleGerman:BEHANDLUNG NICHT ALKOHOLINDUZIERTER FETTLEBER MITTELS CHOLESTERINSENKENDEN MITTELN UND/ODER H3-REZEPTOR-ANTAGONISTEN ODER -INVERSAGONISTEN[2008/36]
English:TREATMENT OF NONALCOHOLIC FATTY LIVER DISEASE USING CHOLESTEROL LOWERING AGENTS AND/OR H3 RECEPTOR ANTAGONIST/INVERSE AGONIST[2008/36]
French:TRAITEMENT DE LA STEATOSE HEPATIQUE NON ALCOOLIQUE AU MOYEN D'AGENTS HYPOCHOLESTEROLEMIANTS ET/OU DUN AGONISTE INVERSE/ANTAGONISTE DU RECEPTEUR H3[2008/36]
Entry into regional phase28.03.2008National basic fee paid 
28.03.2008Designation fee(s) paid 
28.03.2008Examination fee paid 
Examination procedure28.03.2008Examination requested  [2008/36]
04.09.2008Amendment by applicant (claims and/or description)
27.04.2009Despatch of a communication from the examining division (Time limit: M06)
19.10.2009Reply to a communication from the examining division
31.03.2010Despatch of a communication from the examining division (Time limit: M06)
11.10.2010Application deemed to be withdrawn, date of legal effect  [2011/13]
12.11.2010Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time  [2011/13]
Fees paidRenewal fee
08.12.2008Renewal fee patent year 03
07.12.2009Renewal fee patent year 04
22.11.2010Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[Y]WO0232893  (SCHERING CORP [US]) [Y] 1-48 * the whole document *;
 [Y]WO03033488  (SCHERING CORP [US]) [Y] 1-48 * the whole document *
 [Y]  - KOTEISH AYMAN ET AL, "Animal models of steatohepatitis.", BEST PRACTICE & RESEARCH. CLINICAL GASTROENTEROLOGY OCT 2002, (200210), vol. 16, no. 5, ISSN 1521-6918, pages 679 - 690, XP002429939 [Y] 1-48 * the whole document * * page 686 *

DOI:   http://dx.doi.org/10.1053/bega.2002.0332
 [Y]  - TOTH PETER P ET AL, "Simvastatin plus ezetimibe: combination therapy for the management of dyslipidaemia.", EXPERT OPINION ON PHARMACOTHERAPY JAN 2005, (200501), vol. 6, no. 1, ISSN 1744-7666, pages 131 - 139, XP009082392 [Y] 1-48 * abstract * * 2.2 page 133 * * 3.2 page 134 *

DOI:   http://dx.doi.org/10.1517/14656566.6.1.131
 [PY]  - AHMED MOHAMED H ET AL, "Ezetimibe: effective and safe treatment for dyslipidaemia associated with nonalcoholic fatty liver disease. Response to: Toth PP, Davidson MH: simvastatin and ezetimibe: combination therapy for the management of dyslipidaemia. Expert Opin. Pharmacother. (2005) 6(1):131-139.", EXPERT OPINION ON DRUG SAFETY JUL 2006, (200607), vol. 5, no. 4, ISSN 1744-764X, pages 487 - 488, XP002429940 [PY] 1-48 * page 488, column 2, line 10 - line 14 *

DOI:   http://dx.doi.org/10.1517/14740338.5.4.487
 [Y]  - FARNIER MICHEL ET AL, "Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia.", EUROPEAN HEART JOURNAL MAY 2005, (200505), vol. 26, no. 9, ISSN 0195-668X, pages 897 - 905, XP002429941 [Y] 1-48 * the whole document *

DOI:   http://dx.doi.org/10.1093/eurheartj/ehi231
 [Y]  - HANCOCK A A ET AL, "Histamine H3 antagonists in models of obesity", INFLAMMATION RESEARCH, (200403), vol. 53, no. Suppl. 1, ISSN 1023-3830, pages S47 - S48, XP002429942 [Y] 1-48 * the whole document *

DOI:   http://dx.doi.org/10.1007/s00011-003-0322-5
 [Y]  - FEY THOMAS A ET AL, "Effects of A-423579, a Novel Histamine-3 Receptor Antagonist in Rodent Models of Diet-Induced Obesity", FASEB JOURNAL, & FASEB MEETING ON EXPERIMENTAL BIOLOGY: TRANSLATING THE GENOME; WASHINGTON, DISTRICT OF COLUMBIA, USA; APRIL 17-21, 2004, (2004), vol. 18, no. 4-5, ISSN 0892-6638, page ABST. 394.5, XP009082414 [Y] 1-48 * the whole document *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.